Compare Abeona Therapeutics Inc (ABEO) vs Transocean Ltd (RIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Transocean Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.81 (market cap $373.32M), while Transocean Ltd trades at $5.23 (market cap $5.56B). The key difference: Transocean Ltd is far larger — about 14.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | RIG | |
|---|---|---|
Market Cap | $373.32M | $5.56B |
Sector | Health | Technology |
52-Week High | $7.23 | $7.58 |
52-Week Low | $4.17 | $2.55 |
Enterprise Value | $228.22M | $10.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Transocean Ltd. (RIG) trades at $4.93, down 2.57% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported a net loss of $2.92 billion in 2025 despite $3.97 billion revenue, though recent contract wins including a $1 billion Equinor deal and the pending Valaris merger aim to strengthen backlog and reduce leverage. Analyst consensus is divided with 39% buy ratings and a $7.00 price target, 42% above current levels.
RIG presents a high-risk opportunity with significant upside potential if operational improvements and merger synergies materialize. Key risks include persistent net losses, oil price volatility, and execution challenges from the Valaris integration. The stock's below-book valuation (P/B 0.56) and strong revenue backlog provide a margin of safety, but investors must weigh the turnaround potential against ongoing profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
